This product is a box of 10 vials.
What is AOD9604?
AOD9604 is a modified version of GH fragment 176-191. Developers first made AOD9604 as an anti-obesity medication because of its fat-burning qualities. People value this peptide since its effects are mostly limited to fat reduction. It doesn't seem to influence IGF-1 levels or insulin levels, thus there is minimal risk for glucose intolerance or diabetes. Also, no signs point to the body creating antibodies against AOD9604, given its structure closely resembles HGH.
Sequence:
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe Disulfide bridge Cys7-Cys15
Molecular Formula: C78H123N23O23S2
Molecular Weight: 1815.12 g/mol
PubChem CID:Â 16131447
CAS Number: 386264-39-7
Obesity
AOD9604 started as an HGH analog aimed specifically at combating fat. In Australia, phase 2b clinical trials wrapped up testing the drug on 300 obese people. Over 12 weeks with daily doses, results showed the peptide tripled weight loss compared to a placebo. Plus, the weight loss pace held steady throughout the trial. This consistency suggests resistance to the peptide is unlikely, and longer use could lead to even more weight reduction.
Studies on mice prone to obesity due to genetics show AOD9604 probably doesn't act solely through beta-3-adrenergic receptors on white fat. Early theories suggested the peptide attached to these receptors and sped up metabolism in fat cells, switching them from storage to energy use. Yet, even in mice without those receptors, fat loss occurred with AOD9604 treatment. While the beta-3-adrenergic receptor might contribute to fat loss from AOD9604, another process must be involved too. Some believe AOD9604 could indirectly trigger cell death in white fat cells.
Joint Pain & Function
Rat studies show that injecting AOD9604 straight into arthritic joints can pair with current treatments to ease pain, lessen disability, and boost life quality. Improvements in both overall clinical checks and tiny cartilage structures in damaged joints point to AOD9604 tackling osteoarthritis' root causes. It might serve as both a cure and a preventive measure. AOD9604 reduces joint issues on its own, but it performs even better alongside other modalities. The exact way this synergy happens remains unclear, yet more peptide studies could uncover fresh paths for better cartilage growth.
Heart Disease
While cutting fat and losing weight directly lower heart disease risk, evidence hints that AOD9604 aids the heart beyond just slimming down. The peptide might directly modify metabolism apart from its effects on obesity. This isn't unusual, since drugs like pioglitazone and acipimox can correct metabolic issues without a reduction in extra weight. Experts think AOD9604's secondary fat-loss route, separate from beta-3-adrenergic receptor startup, could improve metabolic health while enhancing fat reduction.
Curious about AOD9604?
Join our Facebook group to engage directly with thousands of others who use this product, and follow our Facebook/IG pages for hot updates and product announcements!